Beneficial effects from stem-cell infusion in muscular dystrophy, when observed, typically persist for 6–18 months before disease progression resumes. Some patients have received repeated infusions at 6–12 month intervals to sustain any achieved benefit. Durability correlates with cell engraftment and ongoing immune tolerance; immunological rejection or graft attrition shortens duration. Longer-term follow-up data beyond 2 years remain limited, so sustained multi-year benefit cannot yet be reliably predicted. Disease biology itself — progressive genetic degeneration — means even stable benefit may eventually be overwhelmed by continuing pathological decline.
Muscular dystrophies encompass a family of progressive genetic disorders affecting muscle strength and integrity. Stem-cell research investigates whether placental mesenchymal stem cells (MSCs) and fetal stem cells can integrate into damaged muscle tissue, secrete anti-inflammatory factors, and halt the cascade of degeneration characteristic of conditions like Duchenne muscular dystrophy. The approach targets both direct muscle regeneration through cell fusion and paracrine effects that reduce inflammation and fibrosis. With 26 registered trials and 4 currently recruiting participants, early-phase data suggests MSCs may slow progression, particularly when infused systemically or injected locally into affected muscles. The neuromuscular pathology — characterised by dystrophin loss and calcium dysregulation — creates a uniquely hostile environment for transplanted cells, making efficacy variable and recovery timescales extended.
Съм ли кандидат? → · Muscular Dystrophy: full overview → · Цена Мускулна дистрофия → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка